Redeye comments on Raketech’s preannounced Q4-results which were lower than expected while the compa...
Redeye returns with a more in-depth take on OssDsign’s Q4 report.
Redeye maintains its fair value range for Sleep Cycle following the Q4 2024 report, which met our sa...
Q4 a tad soft at 5% organic growth and EBIT -6% But the undelrying business appears in very good sha...
Probi avslutar sin 20-åriga resa på börsen – detta med flaggan i topp.
Kingspan bids SEK 182.5/shareNWG's board recommends accepting the bidHighly likely the bid will go t...
Redeye sees another strong quarter for OssDsign as sales beat our estimates with a continuing robust...
Den 3 februari 2025 meddelade AcuCort (”AcuCort” eller ”Bolaget”) utfallet i företrädesemissionen, v...
We anticipate Vaisala’s profitable growth journey to take a leap in 2025 aided by acquisitions.
Beat in Q4 driven by higher sales EBIT +7% vs ABGSCe Estimates likely to be revised up 2-5% on EBIT ...
Redeye is encouraged by the healthy rebound in demand witnessed in Ependion’s Q4 report.
Redeye initiates coverage of Corline Biomedical, a Swedish medtech/biotech company specialising in c...
Medical has stabilised following a period of volatile margins More margin expansion left, Medical to...
DT reports Q4 results on Feb 6. We make limited estimate revisions ahead of the report as outlook re...
Dovre completed its segmental sale for a significant cash pile, the eventual use of which remains an...
LapWall releases its Q4 result on 6th of February. As the 2024 result is already largely known, our ...
NanoEcho är ett medicintekniskt bolag som utvecklar ett innovativt bildgivande system för tydligare ...
Redeye updates its estimates and valuation on Embracer to reflect the Asmodee spin-off and the stron...
Redeye comments on the ongoing launch in Norway of Terclara.
